Sai Parenterals Shifts IPO Funds for Pharma Acquisitions Amid Strategic Realignment

Sai Parenterals plans to acquire a 60% stake in Saicriti Pharma for Rs 83.83 crore and another 60% in Prathyak Laboratories for Rs 15 crore, totaling Rs 101.85 crore. These funds will be redeployed from its Initial Public Offering (IPO) proceeds originally earmarked for facility upgrades.

Reader Takeaway: IPO funds redirected to acquisitions; FY27 revenue target unchanged.

What just happened

The company announced its Q1 FY27 earnings transcript and strategic updates, revealing a proposal to vary the objects of its IPO issue. The Board has approved the redeployment of Rs 101.85 crore from facility upgrades and R&D to acquire stakes in two pharmaceutical companies. This move is driven by new regulatory guidelines under the Hyderabad Industrial Lands Transformation Policy (HILTP).

Why this matters

This strategic reallocation allows Sai Parenterals to acquire operational assets and expand capacity more rapidly than through internal upgrades. The acquisition of Saicriti Pharma's injectable facility and Prathyak Laboratories' R&D center is expected to significantly enhance the company's product offerings and research capabilities. The company also reaffirmed its FY27 revenue guidance of Rs 750 crore, targeting a 17% EBITDA margin.

The backstory

Sai Parenterals' standalone performance showed significant growth in Q1 FY27, with revenue up 175% year-on-year to Rs 56 crore and PAT growing over elevenfold to Rs 9 crore. Consolidated revenue for Q1 FY27 stood at Rs 182 crore, with an EBITDA margin of 14.9%. The company noted that YoY consolidated comparisons are not directly comparable due to the inclusion of Noumed Pharmaceuticals since November 2025.

What changes now

The company will now focus on integrating the newly acquired pharmaceutical assets. The acquisition of Saicriti Pharma aims to add approximately 154.66 million units of injectable capacity, exceeding the original upgrade plan. Prathyak Laboratories brings an established R&D center with 150 SKUs and 86 molecules, enabling immediate R&D activities.

Risks to watch

Key risks include the dependency on shareholder and regulatory approvals for the acquisitions. Management highlighted that the move to new facilities was prompted by restrictive local regulatory policies. Achieving the targeted 17% EBITDA margin for FY27 depends on mitigating elevated air freight costs due to West Asian supply chain disruptions and successfully scaling new operations.

Peer comparison

While specific peer comparisons were not detailed in the filing, the company's move into critical care injectables and R&D expansion aligns with broader industry trends of vertical integration and capacity enhancement. The renewal of the EBOS contract in Australia for AUD 202 million over 7.5 years also signals a strategic focus on international market penetration.

Context metrics (time-bound)

• Q1 FY27 Standalone Revenue: Rs 56 crore (+175% YoY).
• Q1 FY27 Standalone PAT: Rs 9 crore (over 11x YoY growth).
• Q1 FY27 Consolidated Revenue: Rs 182 crore.
• Q1 FY27 Consolidated EBITDA Margin: 14.9%.
• Proposed Acquisition Funding: Rs 101.85 crore.
• FY27 Revenue Guidance: Rs 750 crore.
• Group Debt (June 30, 2026): Rs 310 crore (Gross Debt-to-Equity: ~0.6x).
• EBOS Contract Value: Approx. AUD 202 million over 7.5 years.

What to track next

Investors should monitor the shareholder approval process for the IPO fund variation and the progress of the acquisitions. The commissioning timeline for the new Gummadidala facility and the recovery of EBITDA margins towards the 17% target will be crucial indicators. The company's foray into the US market via a new subsidiary will also be a point of interest.